24 10, 2019

Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity

By |2019-10-24T09:38:15-08:00October 24th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Although currently available antidepressants increase monoamine levels soon after the start of treatment, therapeutic benefits are often delayed by several weeks and the majority of patients with major depressive disorder fail to achieve an adequate response to first- or second-line therapies targeting monoamines. The recent approval of the NMDA (N-methyl-d-aspartate) [...]

24 10, 2019

Over-the-Counter Device Offers Long-Lasting Pain Relief, New Data Shows

By |2019-10-24T09:28:34-08:00October 24th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

A novel, noninvasive, over-the-counter electromagnetic neuromodulation device (ActiPatch, BioElectronics Corp.) appears to deliver long-lasting relief in chronic pain patients. Results of a long-term prospective study that included 240 patients who had previously experienced chronic pain relief with the device showed that at 6 months, 97% of the 240 participants sustained [...]

29 07, 2019

Benefit Seen in the Use of Intranasal Insulin in Slowing Dementia

By |2019-07-29T16:49:18-08:00July 29th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Daily intranasal insulin may be effective in slowing progression of mild cognitive impairment (MCI) or Alzheimer's disease (AD), new research suggests. The findings were presented at the Alzheimer's Association International Conference (AAIC) 2019. Investigators found intranasal insulin administered via a novel delivery device slowed the rate of cognitive decline by [...]

29 05, 2019

Oral Antipsychotic Versus Long-acting Injections Antipsychotic In Schizophrenia Spectrum Disorder: A Mirror Analysis In A Real-world Clinical Setting

By |2019-05-29T14:08:15-08:00May 29th, 2019|Articles In Press|0 Comments

Nicola Poloni, MD, PhD, Marta Ielmini, MD, PhD Student, Ivano Caselli, MD, PhD Student, Giulia Lucca, MD, Alessandra Gasparini, MD, Giorgia Lorenzoli, MD, Camilla Callegari, MD, PhD ABSTRACT Despite mixed results found in literature, long-acting injectable antipsychotics (LAIs) should offer better efficacy and tolerability, compared to oral antipsychotics due to improved [...]

24 05, 2019

Successful Resolution Of Prominent Somatic Delusions Following Bi-temporal Electroconvulsive Therapy In A Patient With Treatment- Resistant Schizoaffective Disorder

By |2019-05-24T16:20:42-08:00May 24th, 2019|Articles In Press|0 Comments

Joshua L. Cohen, PhD, My-Hanh Thi Vu, MD, Mirza Adam Beg, BS, Soumya Sivaraman, MD, Badari Birur, MD ABSTRACT Somatic delusions occur in a variety of psychiatric disorders including schizophrenia, major depressive disorder, and bipolar disorder. Somatization is associated with lower quality of life and greater risk for suicide. Treatment [...]

24 05, 2019

Involuntary Facial Twitching In A Patient With Schizophrenia On Treatment With Long Acting Injectable Olanzapine

By |2019-05-24T16:18:53-08:00May 24th, 2019|Articles In Press|0 Comments

Feras Ali Mustafa, Agastya Nayar ABSTRACT We report a case of a 49 year old Caucasian male with chronic schizophrenia and a history of non-compliance with treatment, due to lack of insight, resulting in multiple acute psychotic relapses that required compulsory admissions to hospital during which he was treated orally [...]

24 05, 2019

Revisiting Lithium: Utility for Behavioral Stabilization in Adolescents and Adults with Autism Spectrum Disorder

By |2019-05-24T16:14:28-08:00May 24th, 2019|Articles In Press|0 Comments

Mark Mintz, MD and Emma Hollenberg ABSTRACT Objectives To examine the efficacy of lithium as a mood stabilizer for patients with autism spectrum disorder (ASD). Experimental Design A retrospective chart review was performed that examined the use of both extended and immediate release lithium carbonate in patients with ASD that [...]

24 05, 2019

Serum Concentration of Paliperidone Palmitate Administered Every 3 Weeks

By |2019-05-24T16:11:57-08:00May 24th, 2019|Articles In Press|0 Comments

Johan Y. Cohen, Ariane Dumoulin-Charette, Nafaa Meraabi, and Raphaël Poirier ABSTRACT Schizophrenia, a disabling yet relatively common mental illness, is often controlled by antipsychotic drugs. However, long-term treatments are subject to non-adherence and consequent treatment failure. Non-adherence can be reduced by administration of slow-release drugs such as intramuscularly injected (IM) [...]

1 04, 2019

Delayed-Onset Toxicity In An Adolescent Case Following Attempted Suicide With An Overdose Of Paliperidone Intake

By |2019-04-01T18:18:30-08:00April 1st, 2019|Articles In Press|0 Comments

Ferhat Yaylacı, Önder Küçük, and Handan Özek Erkuran ABSTRACT Paliperidone is a relatively novel atypical antipsychotic drug that is currently used to treat schizophrenia in adolescents and adults.  The drug was generated by combining the active metabolite of risperidone, 9- hydroxyrisperidone, with osmotic controlled- release oral administration system (OROS) technology. [...]

1 04, 2019

Identifying Predictors of Primary Adherence to Second Generation Long-Acting Injectable Antipsychotics Following Discharge from an Acute Inpatient Psychiatry Unit

By |2019-04-01T18:16:49-08:00April 1st, 2019|Articles In Press|0 Comments

Jenna L. Gilbert, Leigh Anne Nelson, Pharm.D., BCPP, Carrie R. Kriz, MS, Yifei Liu, B.S. Pharm, Ph.D., Courtney A. Iuppa, Pharm.D., BCPP, Lauren A. Diefenderfer, Pharm.D., BCPP, Ellie S.R. Elliott, Pharm.D., BCPP, and Roger W. Sommi, Pharm.D., BCPP, FCCP Abstract Describe primary adherence and medication persistence to second generation long-acting injectable (LAI) antipsychotics following an inpatient psychiatry [...]